Infectious endophthalmitis in Boston keratoprosthesis: Incidence and prevention

Acta Ophthalmologica

Volumn 92, Issue 7, 2014, Pages e546-e555

  Behlau, Irmgard ^a,b,c   Martin, Kathryn V ^a   Martin, Jacqueline N ^a   Naumova, Elena N ^d   Cadorette, James J ^a   Sforza, J Tammy ^a   Pineda, Roberto ^a   Dohlman, Claes H ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

^d Tufts University   (United States)

Author keywords

Boston keratoprosthesis; endophthalmitis; ocular infections; ocular prophylaxis

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; POLYTRIM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL ENDOPHTHALMITIS; BOSTON KERATOPROSTHESIS; CHEMICAL BURN; DISEASE SURVEILLANCE; ENDOPHTHALMITIS; FOLLOW UP; FUNGAL ENDOPHTHALMITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; INCIDENCE; KERATOPROSTHESIS; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UNITED STATES; VISUAL IMPAIRMENT; BIOARTIFICIAL ORGAN; CORNEA; EYE INFECTIONS, BACTERIAL; EYE INFECTIONS, FUNGAL; HEALTH; MICROBIOLOGY; PHYSIOLOGY; PROSTHESIS IMPLANTATION; RETROSPECTIVE STUDY; RISK FACTOR; VISUAL ACUITY;

ANTIBIOTIC PROPHYLAXIS; BIOARTIFICIAL ORGANS; CORNEA; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; EYE INFECTIONS, FUNGAL; GLOBAL HEALTH; HUMANS; INCIDENCE; PROSTHESIS IMPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VISUAL ACUITY;

EID: 84921588605     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12309     Document Type: Article

References (80)

1. Akpek EK, Harissi-Dagher M, Petrarca R, Butrus SI, Pineda R II, Aquavella JV, &, Dohlman CH, (2007): Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study. Am J Ophthalmol 144: 227-231.
2. Aldave AJ, Kamal KM, Vo RC, &, Yu F, (2009): The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 116: 640-651.
3. Aldave AJ, Sanwan VS, Basu S, et al., (2012): International results with the Boston type I keratoprosthesis. Ophthalmology 119: 1530-1538.
4. Al-Torbak AA, Al-Shahwan S, Al-Jadaan I, Al-Hommadi A, &, Edward DP, (2005): Endophthalmitis-associated with the Ahmed glaucoma valve implant. Br J Ophthlamol 89: 454-458.
5. Alvarez de Toledo J, Barraquer RI, Temprano J, Carreras H, Torres E, &, Barraquer J, (1999): Osteo-odonto-keratoprosthesis: a 30-year retrospective study. An Inst Barraquer 28 (Suppl): 95-100.
6. Ament JD, Pineda R II, Lawson B, Behlau I, &, Dohlman CH, (2009): The Boston International Keratoprosthesis Protocol version 2.0 June 2009. Available at: http://www.masseyeandear.org/gedownload/KPro%20International%20Protocol2.pdf?item-id=5816015&version-id=5816016 (Accessed August 15, 2009).
7. Aquavella JV, Qian Y, McCormick GJ, &, Palakuru JR, (2005): Keratoprosthesis: the Dohlman-Doane device. Am J Ophthalmol 140: 1032-1037.
8. Aquavella JV, Qian Y, McCormick GJ, &, Palakuru JR, (2006): Keratoprosthesis: current techniques. Cornea 25: 656-662.
9. Aquavella JV, Gearinger MD, Akpek EK, &, McCormick GJ, (2007): Pediatric keratoprosthesis. Ophthalmology 114: 989-994.
10. Bajracharya L, Gurung R, &, Tabin F, (2012): Keratoprosthesis, Dohlman type I device for a patient with repeated corneal graft failure. Nepal J Ophthalmol 4: 165-169.
11. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, &, Wilson LA, (1997): The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field electrophoresis. Arch Ophthalmol 115: 357-361.
12. Barnes SD, Dohlman CH, &, Durand ML, (2007): Fungal colonization and infection in Boston keratoprosthesis. Cornea 26: 9-15.
13. Barnham JJ, &, Roper-Hall MJ, (1983): Keratoprosthesis: a long-term view. Br J Ophthalmol 67: 468-474.
14. Behlau I, (2012): Boston keratoprosthesis-associated endophthalmitis: recommendations for prevention. Miami, Fl: 8th kPro Study Group, May 12, 2012.
15. Behlau I, &, Gilmore MG, (2008): Microbial biofilms in ophthalmology and infectious diseases. Arch Ophthalmol 126: 1572-1581.
16. Behlau I, Mukherjee K, Todani A, et al., (2011a): Assessment of biocompatibility and biofilm inhibition of N,N-hexyl-methyl-polyethylenimine attached to Boston keratoprosthesis materials. Biomaterials 32: 8783-9796.
17. Behlau I, Tisdale AS, Martin KV, et al., (2011b): Explanted Boston keratoprosthesis: a scanning electron microscopy study. 27th Biennial Cornea Conference Abstracts, Boston, MA.
18. Behlau I, Martin KV, Martin JN, Walcott-Harris R, Chodosh J, &, Dohlman CH, (2012): Boston keratoprosthesis-associated endophthalmitis: global incidence and recommendations for prevention. OMIG Nov 9, 2012. Available at: eyemicrobiology.upmc.com/2012Abstracts/2012OMIGAbstract3.html.
19. Bezwada P, Clark LA, &, Schneider S, (2008): Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Curr Med Res Opin 24: 419-424.
20. Bradley JC, Hernandez EG, Schwab IR, &, Mannis MJ, (2009): Boston type I keratoprosthesis: the University of California Davis experience. Cornea 28: 321-327.
21. Cade F, Grosskreutz CL, Tauber A, &, Dohlman CH, (2011): Glaucoma in eyes with severe chemical burn, before and after keratoprosthesis. Cornea 30: 1322-1327.
22. Cardona H, &, DeVoe AC,. (1977): Prosthokeratoplasty. Trans Am Acad Ophthalmol 83: 271-280.
23. Chan CC, &, Holland EJ, (2012): Infectious endophthalmitis after Boston keratoprosthesis type I implantation. Cornea 31: 339-467.
24. Chew HF, Ayres BD, Hammersmith KM, Rapuano CJ, Laibson PR, Myers JS, Jin YP, &, Cohen EJ, (2009): Boston keratoprosthesis outcomes and complications. Cornea 28: 989-996.
25. de la Cruz J, &, McMahon T, (2009): Surveillance cultures of contact lenses of patients with Boston kpro type I keratoprosthesis. EVER 330: Oct 2, 2009.
26. de la Cruz J, Behlau I, &, Pineda R, (2007): Case report: atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth generation fluoroquinolone therapy. J Cataract Refract Surg 33: 1318-1321.
27. de la Cruz J, Cortina MS, Chang J-H, &, Azar DT, (2011): Scanning electron microscopy analysis of explanted keratoprostheses. ARVO; D861.
28. Doane MG, Dohlman CH, &, Bearse G, (1996): Fabrication of a keratoprosthesis. Cornea 15: 179-184.
29. Dohlman CH, (1993): Postoperative regimen and repair of complications after keratoprosthesis surgery. Refract Corneal Surg 9: 197-198.
30. Dohlman CH, &, Doane MG, (1994): Some factors influencing outcome after keratoprosthesis surgery. Cornea 13: 214-218.
31. Dohlman CH, &, Terada H, (1998): Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome. Adv Exp Med Biol 438: 1021-1025.
32. Dohlman CH, Schneider HA, &, Doane MG, (1974): Prosthokeratoplasty. Am J Ophthalmol 77: 694-700.
33. Dohlman CH, Dudenhoefer EJ, Khan BF, &, Morneault S, (2002): Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO J 28: 72-74.
34. Dohlman CH, Grosskreutz CL, Chen TC, Pasquale LR, Rubin PA, Kim EC, &, Durand M, (2010): Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery. J Glaucoma 19: 111-115.
35. Dunlap K, Chak G, Aquavella JV, Myrowitz E, Utine CA, &, Akpek E, (2010): Short-term visual outcomes of Boston type I keratoprosthesis implantation. Ophthalmology 117: 687-692.
36. Durand ML, &, Dohlman CH, (2009): Successful prevention of endophthalmitis in eyes with the Boston keratoprosthesis. Cornea 28: 896-901.
37. Etminan M, Forooghian F, Brophy JM, Bird ST, &, Maberley D, (2012): Oral fluoroquinolones and the risk of retinal detachment. JAMA 307: 414-419.
38. Falcinelli G, Falsini B, Taloni M, Colliardo P, &, Falcinelli G, (2005): Modified Osteo-odonto-keratoprosthesis for treatment of corneal blindness. Arch Ophthalmol 123: 1319-1329.
39. Fintelmann RE, Maguire JI, Ho AC, Chew HF, &, Ayres BD, (2009): Characteristics of endophthalmitis in patients with the Boston keratoprosthesis. Cornea 28: 877-878.
40. Garg P, Krishna PV, Stratis AK, &, Gopinathan U, (2005): The value of corneal transplantation in reducing blindness. Eye (Lond) 19: 1106-1114.
41. Georgalas I, Kanelopoulos AJ, Petrou P, Ladas I, &, Gotzaridis E, (2010): Presumed endophthalmitis following Boston keratoprosthesis treated with 25 gauge vitrectomy: a report of three cases. Graefes Arch Clin Exp Ophthalmol 248: 447-450.
42. Gevorgyan O, Hovakimyan A, &, Aldave AJ, (2011): Complications and outcomes of Boston type I keratoprosthesis surgery in Armenia. ARVO; 337.
43. Greiner MA, Li JY, &, Mannis MJ, (2011): Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 118: 1543-1550.
44. Guell JL, Arcos E, Gris O, Aristizabal D, Pacheco M, Sanchez CL, &, Manero F, (2011): Outcomes with the Boston type I keratoprosthesis at Instituto de Microcirugia Ocular IMO. Saudi J Ophthalmol 25: 281-284.
45. Iyer G, Srinivasan B, Gupta N, &, Padmanabhan P, (2012): Outcome of Boston keratoprosthesis in a developing country-importance of patient selection, education, and perioperative care: the Indian experience. Asia Pac J Ophthalmol (Phila) 1: 202-207.
46. Javadi MA, Nasiri N, Salour H, Bagheri A, Karimian F, Jafarinasab MR, &, Faramarzi A, (2006): Outcomes of keratoprosthesis at Labbafinejad Medical Center. Bina J Ophthalmol 11: 362-368.
47. Kamyar R, Wiezer JS, Heiter de Paula F, Stein JD, Moroi SE, John D, Musch DC, &, Mian SI, (2012): Glaucoma associated with Boston type I keratoprosthesis. Cornea 31: 134-139.
48. Kang JJ, de la Cruz J, &, Cortina MS, (2012): Visual outcomes of Boston keratoprosthesis implantation as the primary penetrating corneal procedure. Cornea 31: 1436-1440.
49. Kiang L, Sippel KC, Starr CE, Ciralsky J, Rosenblatt MI, Radcliffe NM, D'Amico DJ, &, Kiss S, (2012): Vitroretinal surgery in the setting of permanent keratoprosthesis. Arch Ophthalmol 130: 487-492.
50. Kim JH, &, Chen TC, (2011): Delayed sterile endophthalmitis after glaucoma drainage implantation. Semin Ophthalmol 26: 290-294.
51. Li JY, Greiner MA, Brandt JD, Lom MC, &, Mannis MJ, (2011): Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis. Am J Ophthalmol 152: 209-218.
52. Magalhaes FP, do Nascimento HM, Ecker DJ, Sannes-Lowery KA, Sampath R, Rosenblatt MI, de Sousa LB, &, de Oliviera LA, (2013): Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% povidone-iodine. Cornea 32: 407-411.
53. Mannis MJ, &, Dohlman CH, (1999): The artificial cornea: a brief history. In:, Mannis MJ, &, Mannis AA, (eds). Corneal transplantation: a history in profiles. (Hirschberg History of Ophthalmology). Oostende, Belgium: JP Wayenborgh, 6 321-335.
54. Mariotti SP, (2010): Global data on visual impairments. World Health Organization. WHO/NMH/PBD/12.01. Available at: http;// www.who.int/blindness/GLOBALDATAFINALforweb.pdf. (Accessed April 23, 2013).
55. Nouri M, Terada H, Alfonso EC, Foster S, Durand ML, &, Dohlman CH, (2001): Endophthalmitis after keratoprosthesis: incidence, bacterial etiologies, and risk factors. Arch Ophthalmol 119: 484-489.
56. Nouri M, Durand ML, &, Dohlman CH, (2005): Sudden reversible vitritis after keratoprosthesis: an immune phenomenon? Cornea 24: 915-919.
57. Ocular Microbiology, Bascom Palmer Eye Institute (2012): Antibiotic susceptibility trends. Available at: http://bascompalmer.org/research-cores/ocular-microbiology/antibiotic-susceptibility-trends. (Accessed 12 March 2012).
58. Ormerod LD, Becker LE, Cruise RJ, et al., (1993a): Endophthalmitis caused by the coagulase-negative staphylococci. 2. Factors influencing presentation after cataract surgery. Ophthalmology 100: 724-729.
59. Ormerod LD, Ho DD, Becker LE, et al., (1993b): Endophthalmitis caused by the coagulase-negative staphylococci. 1. Disease spectrum and outcome. Ophthalmology 100: 715-723.
60. Patel AP, Wu EI, Ritterband DC, &, Seedor JA, (2012): Boston type I keratoprosthesis: the New York Eye and Ear experience. Eye (Lond) 26: 418-425.
61. Pellier de Quengsy G, (1789): Précis ou cours d'opérations sur la chirurgie des yeux. Paris: Didot & Mequignon, vol 1 1789-1790; 91.
62. Ramchandran RS, DiLoreto DA, Chung MM, Kleinman DM, Plotnik RP, Graman P, &, Aquavella JV, (2012): Infectious endophthalmitis in adult eyes receiving Boston type I keratoprosthesis. Ophthalmology 119: 674-681.
63. Ray S, Khan BF, Dohlman CH, &, D'Amico DJ, (2002): Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol 120: 559-566.
64. Rivier D, Paula JS, Kim E, Dohlman CH, &, Grosskreutz DL, (2009): Glaucoma and keratoprosthesis surgery: role of adjunctive cyclophotocoagulation. J Glaucoma 18: 321-324.
65. Robert M-C, Biernacki K, &, Harissi-Dagher M, (2012a): Boston keratoprosthesis type 1 surgery: use of frozen versus fresh corneal donor carriers. Cornea 31: 339-345.
66. Robert M-C, Moussally K, &, Harissi-Dagher M, (2012b): Review of endophthalmitis following Boston keratoprosthesis type 1. Br J Ophthalmol 96: 776-780.
67. Sayegh RR, Ang LPK, Foster S, &, Dohlman CH, (2008): The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol 145: 438-444.
68. Schimel AM, Miller D, &, Flynn HW, (2012): Evolving fluoroquinolone resistance among coagulase-negative staphylococcus isolates causing endophthalmitis. Arch Ophthalmol 130: 1617-1618.
69. Silva JV, de Faria e Sousa SJ, &, Ferrante AM, (2006): Corneal transplantation in developing country: problems associated with technology transfer from rich to poor societies. Acta Ophthalmol Scand 84: 396-400.
70. Smith GTH, &, Taylor HR, (1999): Epidemiology of corneal blindness in developing countries. Refract Corneal Surg 7: 436-439.
71. Stolz AP, Kwitko S, Dal Pizzol MM, Marinho D, &, Rymer S, (2008): Experience with the Doane-Dohlman keratoprosthesis: case reports. Arq Bras Oftalmol 71: 257-261.
72. Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, &, McDonnell PJ, (2005): Endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 123: 613-615.
73. Truax KA, Osgood BJ, de la Cruz J, &, McMahon TT, (2009): Surveillance cultures of bandage contact lenses of patients with Boston type I keratoprosthesis. ARVO; 1494.
74. Tsui I, Uslan DZ, Hubschman J-P, &, Deng SX, (2010): Nocardia farcinica infection of a Baerveldt implant and endophthalmitis in a patient with a Boston type I keratoprosthesis. J Glaucoma 19: 339-340.
75. Utine CA, Tzu JH, &, Akpek EK, (2011a): Clinical features and prognosis of Boston type I keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm 19: 413-418.
76. Utine CA, Tzu JH, Dunlap K, &, Akpek EK, (2011b): Visual and clinical outcomes of explantation versus preservation of the intraocular lens during keratoprosthesis implantation. J Cataract Refract Surg 237: 1615-1622.
77. Verdejo-Gomez L, Pelaez N, Gris O, &, Guell JL, (2011): The Boston type I keratoprosthesis: an assessment of its efficacy and safety. Ophthalmic Surg Lasers Imaging 42: 446-452.
78. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, &, Dohlman CH, (2001): Keratoprosthesis: preoperative prognostic categories. Cornea 20: 19-23.
79. Yu J-F, &, Huang Y-F, (2011): Characteristics of endophthalmitis in patients with the Boston keratoprosthesis (Letter). Cornea 119: 202-203.
80. Zerbe BL, Belin MW, Ciolino JB, & Boston Type 1 Keratoprosthesis Study Group (2006): Results from the multicenter Boston type 1 keratoprosthesis study. Ophthalmology 113: 1779-1784.